Impact of adjuvant immunotherapy on prognosis in esophageal squamous cell carcinoma patients following neoadjuvant immunochemotherapy

IntroductionThe CheckMate-577 trial confirmed that adjuvant nivolumab significantly prolonged disease-free survival (DFS) in patients with esophageal cancer who had residual disease after neoadjuvant chemoradiotherapy (nCRT). However, whether postoperative adjuvant immunotherapy (AIT) is necessary f...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Jiayi Geng, Bengang Hui, Teng Mu, Ni Ping, Runmin Jiang, Xiuyuan Chen, Heng Zhao, Dan zeng duo ji, Xizhao Sui, Yun Li, Xun Wang, Jie Lei
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2026-03-01
Serija:	Frontiers in Oncology
Teme:	adjuvant therapy esophageal squamous cell carcinoma immunochemotherapy immunotherapy neoadjuvant therapy
Online dostop:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1735049/full
Oznake:	Označite Brez oznak, prvi označite!